NCT05798845 2026-03-11
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 2 Recruiting
Clinical Trials
14 trialsNCT05636267 2026-03-09
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Akeso
Phase 1/2 Terminated
NCT04318938 2026-03-02
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT05378763 2026-02-18
PINNACLE
Spectrum Pharmaceuticals, Inc
Phase 3 Suspended
NCT07413952 2026-02-17
Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Not yet recruiting
NCT05714891 2026-02-12
Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT07082179 2026-02-11
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Recruiting
NCT06738160 2026-02-06
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Fudan University
Phase 2 Recruiting
NCT07376382 2026-02-02
SYNSTAR-02
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT07379398 2026-01-30
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07358689 2026-01-22
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06576635 2026-01-20
LUNG-05
University of Illinois at Chicago
Phase NA Recruiting
NCT05089916 2026-01-14
ROSE
AIO-Studien-gGmbH
Phase 2 Active not recruiting
NCT07330037 2026-01-09
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting